[go: up one dir, main page]

WO2020044114A3 - Methotrexate pharmaceutical composition - Google Patents

Methotrexate pharmaceutical composition

Info

Publication number
WO2020044114A3
WO2020044114A3 PCT/IB2019/000949 IB2019000949W WO2020044114A3 WO 2020044114 A3 WO2020044114 A3 WO 2020044114A3 IB 2019000949 W IB2019000949 W IB 2019000949W WO 2020044114 A3 WO2020044114 A3 WO 2020044114A3
Authority
WO
WIPO (PCT)
Prior art keywords
patients
methotrexate
absence
pharmaceutical composition
prior
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2019/000949
Other languages
French (fr)
Other versions
WO2020044114A2 (en
Inventor
Hardik PRAJAPATI
Sandip Mehta
Manish UMRETHIA
Jayanta Kumar Mandal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
FTF Pharma Pvt Ltd
Original Assignee
FTF Pharma Pvt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by FTF Pharma Pvt Ltd filed Critical FTF Pharma Pvt Ltd
Priority to GB2104388.0A priority Critical patent/GB2591681A/en
Publication of WO2020044114A2 publication Critical patent/WO2020044114A2/en
Publication of WO2020044114A3 publication Critical patent/WO2020044114A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Though oral liquid formulations of Methotrexate are advantageous as they can suitably be administered to the patients having swallowing difficulties such as pediatric patients, geriatric patients, stroke patients or patients who are unable to take solid oral therapy, they are not much explored in the prior art. Further, liquid formulations of Methotrexate known in the prior art have not been explored at higher pH and in the absence of additional solubilizing agents. An aim of the present invention is therefore to provide chemically and physically stable liquid pharmaceutical compositions of Methotrexate at higher pH and in the absence of solubilizing agents.
PCT/IB2019/000949 2018-08-29 2019-08-29 Methotrexate pharmaceutical composition Ceased WO2020044114A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GB2104388.0A GB2591681A (en) 2018-08-29 2019-08-29 Methotrexate pharmaceutical composition

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201821032299 2018-08-29
IN201821032299 2018-08-29

Publications (2)

Publication Number Publication Date
WO2020044114A2 WO2020044114A2 (en) 2020-03-05
WO2020044114A3 true WO2020044114A3 (en) 2020-04-09

Family

ID=68582041

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2019/000949 Ceased WO2020044114A2 (en) 2018-08-29 2019-08-29 Methotrexate pharmaceutical composition

Country Status (2)

Country Link
GB (1) GB2591681A (en)
WO (1) WO2020044114A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115778897A (en) * 2022-12-15 2023-03-14 深圳市贝美药业有限公司 Stable methotrexate pharmaceutical preparation and preparation method thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050101605A1 (en) * 2003-11-07 2005-05-12 Ahmed Salah U. Oral liquid formulations of methotrexate
US9259427B2 (en) * 2012-01-06 2016-02-16 Rosemont Pharmaceuticals Ltd Methotrexate composition
US20170246172A1 (en) * 2006-07-21 2017-08-31 Medac Gesellschaft Fuer Klinische Spezialpraepararate Mbh Concentrated methotrexate solutions
US20170312281A1 (en) * 2014-10-29 2017-11-02 Therakind Ltd. Methotrexate formulation

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4474752A (en) 1983-05-16 1984-10-02 Merck & Co., Inc. Drug delivery system utilizing thermosetting gels
US5472954A (en) 1992-07-14 1995-12-05 Cyclops H.F. Cyclodextrin complexation
US5925669A (en) 1994-03-22 1999-07-20 Molecular/Structural Bio Technologies, Inc. Carrier compositions for anti-neoplastic drugs
US5770585A (en) 1995-05-08 1998-06-23 Kaufman; Robert J. Homogeneous water-in-perfluorochemical stable liquid dispersion for administration of a drug to the lung of an animal
SE9502244D0 (en) 1995-06-20 1995-06-20 Bioglan Ab A composition and a process for the preparation thereof
US6383471B1 (en) 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
US6309663B1 (en) 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050101605A1 (en) * 2003-11-07 2005-05-12 Ahmed Salah U. Oral liquid formulations of methotrexate
US20170246172A1 (en) * 2006-07-21 2017-08-31 Medac Gesellschaft Fuer Klinische Spezialpraepararate Mbh Concentrated methotrexate solutions
US9259427B2 (en) * 2012-01-06 2016-02-16 Rosemont Pharmaceuticals Ltd Methotrexate composition
US20170312281A1 (en) * 2014-10-29 2017-11-02 Therakind Ltd. Methotrexate formulation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HANSEN J ET AL: "Kinetics of degradation of methotrexate in aqueous solution", INTERNATIONAL JOURNAL OF PHARMACEUTICS, ELSEVIER, NL, vol. 16, no. 2, 1 September 1983 (1983-09-01), pages 141 - 152, XP023844715, ISSN: 0378-5173, [retrieved on 19830901], DOI: 10.1016/0378-5173(83)90051-0 *

Also Published As

Publication number Publication date
GB202104388D0 (en) 2021-05-12
WO2020044114A2 (en) 2020-03-05
GB2591681A (en) 2021-08-04

Similar Documents

Publication Publication Date Title
SI2529622T1 (en) Bruton tyrosine kinase inhibitors
RU2470642C2 (en) Pterin analogues for treating bh4 sensitive condition
TW200744677A (en) Compositions and methods for preparation of poorly water soluble drugs with increased stability
PH12020550341A1 (en) Niraparib formulations
MD20070267A (en) Gastroresistant pharmaceutical formulation containing rifaximin
DE60121301D1 (en) Flibanserin for the treatment of extrapyramidal movement disorders
WO2018165404A8 (en) Pharmaceutical formulations of phloroglucinol and trimethylphloroglucinol
HUP0105173A2 (en) Dosage regimen and pharmaceutical composition for emergency contraception
EP1365749A4 (en) PREPARATION OF PHARMACEUTICAL COMPOSITIONS FOR USE WITH SOFT GELATINE FORMULATIONS
MX388825B (en) USE AND DOSAGE OF THERAPEUTIC AGENTS FOR ENDOMETRIOSIS.
HRP20230929T1 (en) Stable semaglutide compositions and uses thereof
TW200633978A (en) 2,3,4,9-tetrahydro-1H-carbazole derivatives as crth2 receptor antagonists
ATE348602T1 (en) NANOPARTICLES FOR ADMINISTRATION OF ACTIVE INGREDIENTS, METHOD FOR PRODUCING THESE PARTICLES AND THE COMPOSITION CONTAINING THEM
MX390101B (en) Medical treatment comprising enteral administration of edaravone
MX2010004556A (en) Pharmaceutical formulation of clavulanic acid.
MX2020013291A (en) Alkoxy-substituted pyridinyl derivatives as lpa1 receptor antagonists and their use in the treatment of fibrosis.
WO2020044114A3 (en) Methotrexate pharmaceutical composition
WO2023201299A8 (en) Pharmaceutical compositions of therapeutic proteins and methods of use
BR112021006527A2 (en) silicic acids for use in the treatment of periodontitis
BR112017025527A2 (en) liquid pharmaceutical preparation, and method for making a cellocoxib suspension.
EP4556025A3 (en) Formulations of docetaxel
TW200505429A (en) Pharmaceutical composition
WO2019162756A3 (en) Liquid pharmaceutical compositions of anticancer drugs
WO2018069805A3 (en) Method for preparation of liquid oral composition of l-thyroxin
ZA202301927B (en) Phytonadione compositions

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19804820

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 202104388

Country of ref document: GB

Kind code of ref document: A

Free format text: PCT FILING DATE = 20190829

122 Ep: pct application non-entry in european phase

Ref document number: 19804820

Country of ref document: EP

Kind code of ref document: A2